Cargando…
Preliminary experience of tigecycline treatment in critically ill children with ventilator-associated pneumonia
OBJECTIVE: Ventilator-associated pneumonia (VAP) is a life-threatening complication for children who are treated in a paediatric intensive care unit. Tigecycline treatment of children with VAP has not been well studied. This study aimed to describe tigecycline use in children with VAP in a tertiary...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113491/ https://www.ncbi.nlm.nih.gov/pubmed/29614915 http://dx.doi.org/10.1177/0300060518760435 |
_version_ | 1783513682935808000 |
---|---|
author | Lin, Shupeng Liang, Lingfang Zhang, Chenmei Ye, Sheng |
author_facet | Lin, Shupeng Liang, Lingfang Zhang, Chenmei Ye, Sheng |
author_sort | Lin, Shupeng |
collection | PubMed |
description | OBJECTIVE: Ventilator-associated pneumonia (VAP) is a life-threatening complication for children who are treated in a paediatric intensive care unit. Tigecycline treatment of children with VAP has not been well studied. This study aimed to describe tigecycline use in children with VAP in a tertiary care hospital. METHODS: We conducted a retrospective chart review in a tertiary hospital from May 1, 2012 to May 1, 2017. RESULTS: Twenty-four children (20 girls) with median age of 8 months (range, 27 days to 6 years and 9 months) were treated with tigecycline. In-hospital mortality was 41.7% (10/24). The primary diagnosis was congenital heart disease (15/24). A total of 70.8% (17/24) of patients received a loading dose (1.5 mg/kg), followed by 1 mg/kg every 12 hours. The median duration of tigecycline therapy was 10.75 days (range, 3–21.5 days). Sulperazone was the most frequently used concomitant antibiotic. Eighteen pathogens were isolated in 16 cases. Tigecycline therapy failed in 41.6% (10/24) of patients and 20.8% (5/24) died. The pathogen was eradicated in 37.5% (6/16) of patients. No serious adverse effects were detected. CONCLUSION: Tigecycline combined with other agents as salvage therapy in children with VAP is well tolerated. Our preliminary results show a positive clinical response. |
format | Online Article Text |
id | pubmed-7113491 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-71134912020-04-09 Preliminary experience of tigecycline treatment in critically ill children with ventilator-associated pneumonia Lin, Shupeng Liang, Lingfang Zhang, Chenmei Ye, Sheng J Int Med Res Special Issue: Management of Patients With Sepsis and Septic Shock OBJECTIVE: Ventilator-associated pneumonia (VAP) is a life-threatening complication for children who are treated in a paediatric intensive care unit. Tigecycline treatment of children with VAP has not been well studied. This study aimed to describe tigecycline use in children with VAP in a tertiary care hospital. METHODS: We conducted a retrospective chart review in a tertiary hospital from May 1, 2012 to May 1, 2017. RESULTS: Twenty-four children (20 girls) with median age of 8 months (range, 27 days to 6 years and 9 months) were treated with tigecycline. In-hospital mortality was 41.7% (10/24). The primary diagnosis was congenital heart disease (15/24). A total of 70.8% (17/24) of patients received a loading dose (1.5 mg/kg), followed by 1 mg/kg every 12 hours. The median duration of tigecycline therapy was 10.75 days (range, 3–21.5 days). Sulperazone was the most frequently used concomitant antibiotic. Eighteen pathogens were isolated in 16 cases. Tigecycline therapy failed in 41.6% (10/24) of patients and 20.8% (5/24) died. The pathogen was eradicated in 37.5% (6/16) of patients. No serious adverse effects were detected. CONCLUSION: Tigecycline combined with other agents as salvage therapy in children with VAP is well tolerated. Our preliminary results show a positive clinical response. SAGE Publications 2018-04-03 /pmc/articles/PMC7113491/ /pubmed/29614915 http://dx.doi.org/10.1177/0300060518760435 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Special Issue: Management of Patients With Sepsis and Septic Shock Lin, Shupeng Liang, Lingfang Zhang, Chenmei Ye, Sheng Preliminary experience of tigecycline treatment in critically ill children with ventilator-associated pneumonia |
title | Preliminary experience of tigecycline treatment in critically ill
children with ventilator-associated pneumonia |
title_full | Preliminary experience of tigecycline treatment in critically ill
children with ventilator-associated pneumonia |
title_fullStr | Preliminary experience of tigecycline treatment in critically ill
children with ventilator-associated pneumonia |
title_full_unstemmed | Preliminary experience of tigecycline treatment in critically ill
children with ventilator-associated pneumonia |
title_short | Preliminary experience of tigecycline treatment in critically ill
children with ventilator-associated pneumonia |
title_sort | preliminary experience of tigecycline treatment in critically ill
children with ventilator-associated pneumonia |
topic | Special Issue: Management of Patients With Sepsis and Septic Shock |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113491/ https://www.ncbi.nlm.nih.gov/pubmed/29614915 http://dx.doi.org/10.1177/0300060518760435 |
work_keys_str_mv | AT linshupeng preliminaryexperienceoftigecyclinetreatmentincriticallyillchildrenwithventilatorassociatedpneumonia AT lianglingfang preliminaryexperienceoftigecyclinetreatmentincriticallyillchildrenwithventilatorassociatedpneumonia AT zhangchenmei preliminaryexperienceoftigecyclinetreatmentincriticallyillchildrenwithventilatorassociatedpneumonia AT yesheng preliminaryexperienceoftigecyclinetreatmentincriticallyillchildrenwithventilatorassociatedpneumonia |